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a  b  s  t  r  a  c  t
This  investigation  analyzed  the  immunoexpression  of  FasL,  Fas,  cleaved  caspase-8,  and  cleaved  caspase-3
in  glioblastomas.  Formalin-ﬁxed  and  parafﬁn-embedded  glioblastoma  tissues  and  control  brain  tis-
sues  from  97 patients  were  analyzed  by  tissue  microarrays  and  immunohistochemistry.  Patients  with
glioblastomas  that  were  negative  or  weakly  stained  (<50%  of cells  positive)  for cleaved  caspase-8  had
worse  cancer-speciﬁc  overall  survival  (median  =  8.5 months)  than  did  patients  with tumors  that  highly
expressed  cleaved  caspase-8  (median  = 11.7 months;  P = 0.0325),  independent  of clinical  variables.  There
was  no  association  of  other  markers  with  survival,  treatment,  sex,  age,  tumor  size, and  primary  site.
Among  the  tumors,  there  were  reasonable  to good  positive  correlations  between  the  expression  of FasLurvival
aspase  3
and  Fas  (r  = 0.47)  and  between  Fas and  cleaved  caspase-8  (r =  0.41),  and there  were  poor  positive  corre-
lations  between  Fas  and  cleaved  caspase-3  (r =  0.26),  FasL  and  cleaved  caspase-8  (r  = 0.22), and  cleaved
caspase-8  and  -3  (r =  0.31).  Our  results  suggest  that Fas-Fas-ligand  signal  transduction  could  be  inhibited,
especially  at  the  stage  of  caspase-8  activation,  thereby  establishing  a major  mechanism  for  evasion  of
apoptosis  by  these  tumors.  The  absence  or low  expression  of  cleaved  caspase-8  in the tumors  was  a
negative  prognostic  indicator  for  patient  survival.
©  2014  Elsevier  GmbH.  Open access under CC BY-NC-ND license.ntroduction
Glioblastoma (GBM) is the most common malignant primary
rain cancer, and it has a dismal outcome. Despite advances in
iagnosis and treatment, the median survival of patients who suf-
er from GBM remains approximately 15 months, according to
he more recent studies with temozolomide, because of inherent
esistance to both chemo- and radiotherapy [8,9]. For decades,
urgery and radiotherapy have been the traditional cornerstones
 Presented in part: 28th International Congress of the International-Academy-of-
athology, Int Acad Pathol, São Paulo, Brazil, 10–15 October 2010 (Histopathology
010;  57 [Suppl 1]:200).
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Open access under CC BY-NC-ND license.of therapy for GBM. Several chemotherapeutic agents, including
the nitrosourea derivatives and temozolomide, have also been used
with limited success, resulting in median survival times of 12–15
months and long-term remissions in a few temozolomide patients
[9,39]. The poor efﬁcacy of these agents is mostly attributed
to the highly mutated genome of GBM, which is manifested
by the deregulation of many key signaling pathways involving
growth, proliferation, survival, and apoptosis [24]. Moreover, O6-
methylguanine-DNA methyltransferase (MGMT), a repair protein
that speciﬁcally removes promutagenic alkyl groups from the O6
position of guanine in DNA, protects cells against alkylating drugs,
resulting in resistance of GBM to these chemotherapeutic agents
[25].
Apoptosis is a basic biological process that promotes survival of
the organism at the expense of individual cells. It is widely used by
multicellular organisms to remove undesirable cells without injur-
ing neighboring cells or eliciting an inﬂammatory reaction [32].
Nevertheless, tumor cells can evade apoptosis, and thus perturb
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he balance between apoptosis and cell proliferation [14]. Because
ytotoxic drugs and radiation therapy induce tumor cells to die by
poptosis, understanding the mechanisms involved in the extrinsic
poptotic signaling pathway in glioblastomas may  identify target
olecules for molecular therapies.
The activation of the extrinsic apoptotic pathway following Fas
inding has been well characterized [1,40]. Fas ligand (FasL) is a
ype II membrane protein with an intracellular domain that con-
ains consensus sequences for phosphorylation and an extended
roline-rich region that tightly regulates FasL surface expression
n the nervous system [41]. Fas (APO-1/CD95) is a 48-kDa type
 membrane protein with a cysteine-rich extracellular domain
f 155 amino acids. The triggering of Fas by its ligand induces
poptosis in target cells. Although Fas is ubiquitous in human
issues, it is highly expressed in rapidly proliferating cells and
njured tissues [29]. The oligomerization of Fas by FasL recruits
he adaptor molecule Fas-associated death domain protein (FADD)
o the death domain (DD) of the Fas intracellular region [4,7].
rocaspase-8 (FLICE/MACH1/Mch5), in turn, associates with FADD
o form the death-inducing signaling complex (DISC), whereby
rocaspase-8 converts itself to an active cleaved form [4,27]. Next,
he cleaved caspase-8 activates the downstream effector, caspase-
 [21]. Previous reports have demonstrated that the extrinsic
poptotic pathway is severely inhibited in high-grade gliomas
2,13,14,16,19,26,33,35,44].
Several ﬁndings have indicated that the deregulation of apo-
tosis is involved in the development of malignant gliomas. The
pregulated expression of FasL and downregulated expression of
aspase-3 and caspase-8 in malignant glioma cells are involved in
liomagenesis [19,42]. For example, FasL is implicated in glioblas-
oma growth and invasion through the induction of apoptosis
n inﬁltrating lymphocytes, which facilitate the evasion of the
mmune system by the tumor [19]. In addition, it has been shown
hat glioblastomas are resistant to Fas-related apoptosis, showing
bsent or low levels of caspases-8 and caspase-3 [2,33,38,42].
Because the extrinsic apoptotic pathway in treatment-naïve
uman GBMs has not yet been systematically studied, we  aimed
o determine the expression of FasL, Fas, cleaved caspase-8, and
leaved caspase-3 in not otherwise speciﬁed GBMs using tis-
ue microarrays and immunohistochemistry and to correlate the
xpression of these molecules with various clinical ﬁndings. We
lso reviewed the molecular basis of Fas-mediated apoptosis in
alignant gliomas.
aterials and methods
issues
Glioblastoma  specimens from 97 patients who  had not been
reviously treated were retrieved from the archives of the Depart-
ents of Pathology at São Paulo Federal University (n = 60) and
ibeirão Preto Medicine Faculty at São Paulo University (n = 37).
he tumor specimens were re-examined and conﬁrmed to be
lioblastomas according to the criteria of the most recent WHO
lassiﬁcation of Central Nervous System Tumors [22]. All of the
atients had undergone surgery during the 15-year period from
992 through 2006. This study was approved by the Ethics Commit-
ees of both institutions (Resolution No. 196 of Brazilian National
ealth Council).
issue  microarrays (TMAs)Histological  sections (4 m)  were cut from each tissue block,
tained by hematoxylin–eosin, and carefully reviewed by 3 inde-
endent pathologists. The areas most representative of each tumor and Practice 210 (2014) 267–273
were  selected for analysis. Cylindrical cores were removed and used
in the construction of tissue microarray (TMA) blocks. Five TMA
blocks were constructed using a Beecher tissue array instrumentTM
(Beecher Instruments, Silver Spring, MD,  USA), according to the
manufacturer’s instructions, in the following stages: (1) Two dif-
ferent areas of the tumor were marked in the original donor block
for sampling (necrotic zones and perinecrotic palisading cells were
not included in the samples), (2) cylindrical holes were created
in the receptor block using the TMA  platform. Positions were cre-
ated in the receptor blocks and were separated by approximately
500 m such that a matrix of holes for the tissue samples was cre-
ated, (3) 1-mm diameter cylinders of tissue were extracted from the
areas of interest in the donor blocks using a 1-mm-diameter needle
(TMArrayer Punch Beecher InstrumentsTM), (4) the cylindrical tis-
sues obtained from the donor blocks were transferred to the holes
in the receptor blocks, and (5) ﬁnally, the quality of the blocks (rep-
resentativeness of the tumor samples) was assessed before storage.
Twenty-ﬁve control cores obtained from normal brains har-
vested from 25 autopsied patients (6–12 h postmortem) were
included as controls.
Immunohistochemistry
The  immunohistochemical procedures were performed on 4-
m-thick sections that were obtained from the TMA  blocks and
mounted on slides pretreated with 3-minopropyl-triethoxysilane
(Sigma).  To aid in the adhesion of the slices from the TMA  blocks
to the silane-treated slides, an adhesive tape system (Instrumedics
Inc., Hackensak, NJ, USA) was  also used.
Brieﬂy, for immunostaining, the slides were deparafﬁnized, and
rehydrated through a graded ethanol series. For antigen retrieval,
slides were placed in a 0.01 M citrate buffer (pH 6.0), heated in
a steam bath for 3 min, and allowed to cool at room tempera-
ture for 30 min. Endogenous peroxidase activity was blocked using
3% hydrogen peroxide for 15 min, followed by washing in 0.05 M
Tris buffer (pH 9.5). The slides were then subjected to microwave
irradiation at 700 W for 7 min. The slides were again placed in phos-
phate buffered saline (0.01 M PBS [pH 7.4]) and allowed to cool
at room temperature for 30 min. All of the immunomarkers that
were evaluated were examined on slides that underwent treat-
ment for antigen retrieval. The endogenous biotin was  blocked
using 0.02 M PBS/0.3% Triton X100 (pH 7.4) and 5% skim milk
for 4 h at room temperature. Incubation with anti-FasL rabbit
polyclonal antibody (C-178, 1:500; Santa Cruz Biotechnology),
anti-Fas rabbit polyclonal antibody (FL-335, 1:200; Santa Cruz
Biotechnology), anti-cleaved caspase-8 mouse monoclonal anti-
body (AP1013, 1:100; Calbiochem), anti-cleaved caspase-3 rabbit
polyclonal antibody (AP1027, 1:500; Calbiochem), anti-IDH1 rab-
bit polyclonal antibody (AP7454a, 1:50; Abgent), or anti-MGMT
mouse monoclonal antibody (SPM287, 1:150; Santa Cruz Biotech-
nology) diluted in PBS with 1.0% bovine serum albumin (Sigma,
USA) lasted for 12 h in a moist chamber at 4 ◦C. The slides were
then washed in PBS and incubated with secondary biotinylated
antibody followed by streptavidin–biotin-peroxidase (anti-mouse
or anti-rabbit Kit LSAB, DAKO) for 30 min  each. Finally, to visualize
the reactions, the slides were incubated with light-sensitive 3,3′-
diaminobenzidine tetrahydrochloride (Sigma) in 0.05 M PBS (pH
7.6) and quickly counterstained with Harris hematoxylin. Cover-
slips were applied using Entellan (Sigma). A positive reaction was
visualized as a brown deposit in the cell that indicated an area
where the antigen–antibody reaction had occurred. Negative and
positive controls were run simultaneously. Lymphoid tonsil tissue
with follicular germinative centers was  used as a positive control
for FasL, Fas, cleaved caspase-8, and cleaved caspase-3. Placenta
and normal colon, which had immunohistochemistry performed
separately from the TMAs, were used as positive controls for IDH1
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Table 1
Clinical data of patients with glioblastomas.
Characteristics No. (%)
Gender Male 53 (54.6)
Female  44 (45.4)
Age ≥50 years 63 (64.9)
<50  years 34 (35.1)
Tumor sizea
Supratentorial ≤5 cm 5 (9.1)
>5  cm 7 (12.7)
>5  cm with ventricular invasion or
compression
33 (60)
>5  cm with middle-line crossover or
infratentorial invasion
6 (10.9)
Infratentorial >5 cm 4 (7.3)
Primary site
Frontal lobe 25 (25.8)
Parietal  lobe 6 (6.2)
Temporal  lobe 12 (12.4)
Occipital  lobe 1 (1.0)
Supratentorial  sitesb 46 (47.4)
Infratentorial  4 (4.1)
Not  available 3 (3.1)
Follow-upc
Alive at 1 year 29 (38.7)
Alive  at 2 years 8 (10.7)
Alive  at 3 years 3 (4)
Alive  at >3 to 5 years 1 (1.3)
Lost  10 (10.3)F.P. Saggioro et al. / Pathology – Re
nd MGMT,  respectively. Negative controls consisted of slides that
nderwent the same procedure, except the incubation with pri-
ary antibody was eliminated.
The staining patterns were analyzed according to their distri-
ution and intensity, and the pathologists were blinded to the
linicopathological data of the GBM patients. A numerical scoring
ystem consisting of 2 categories was used to assess FasL, Fas,
leaved caspase-8 and cleaved caspase-3 expression. Category A
ocumented the number of immunoreactive cells (only ones with
heir respective nuclei inside were counted) as follows: 0 or neg-
tive (no immunoreactive cells or <10% immunoreactive cells), 1
≥10% and <50% immunoreactive cells), or 2 (≥50% immunoreac-
ive cells).
Category B documented the intensity of the immunostaining
s follows: 0 or 1 (no immunostaining or weak staining, respec-
ively) or 2 (moderate or strong). The values for categories A and
 were summed to provide an “immunoreactivity score”, which
ould range from 0 to 4. Scores of 0, 1, and 2 were considered to
e negative to weak immunoreactivity and called “low immunoex-
ression”. Scores of 3 (moderate) and 4 (strong) were considered
o be “high immunoexpression”.
IDH1  immunostaining was scored in the nuclei and/or cyto-
lasm, and MGMT  were scored in the nuclei of tumor cells as
egative (no stain or limited to <10% positive tumor cells) or posi-
ive (≥10% tumor cells).
tatistical  analysis
The  immunohistochemistry scores determined for FasL, Fas,
leaved caspase-8, and cleaved caspase-3 expression of the
MAs and control nervous tissues were compared using the
ann–Whitney test, and correlations in each group were deter-
ined using the nonparametric Spearman test.
To construct the survival curves illustrating overall survival
etween the patient groups with “low expression” (scores 0, 1, and
) vs. “high expression” (scores 3 and 4) immunohistochemistry
cores  for FasL, Fas, cleaved casp-8 and -3, IDH1, and MGMT,  we
sed the Kaplan–Meier method. To compare the overall survival
urves, we used the log-rank test.
To simultaneously analyze the prognostic effect of the vari-
us factors (treatment, age, gender, tumor size, tumor location,
nd the immunoexpression scores of low and high expression of
asL, Fas, cleaved caspase-8, and -3) on the time of survival, we
sed a multivariate analysis with the Cox proportional-hazards
egression model using a covariate of primary interest and adjust-
ent covariates. All statistical analyses and graph constructions
ere performed using GraphPad Prism version 4.00 for Windows
GraphPad Software Inc., San Diego, CA, USA), and SAS version 9
or Windows (SAS Institute, Inc.; Cary, NC, USA). The level of signif-
cance was 0.05 (P < 0.05). Unless speciﬁed, data are presented as
he mean ± SD or median.
esults
ge and sex distribution
The  mean age of patients at diagnosis was 55.5 ± 14 years (range,
8–78 years; median = 56 years), with 64.9% of patients ≥50 years
f age, and 35.1% <50 years. The age distribution of patients was as
ollows: <39 years, 12.4%; 40–49 years, 22.7%; 50–59 years, 23.7%;
0–69 years, 26.8%; and ≥70 years, 14.4%. The female/male ratio
as 0.8:1 (Table 1). There were no differences in the survival among
he age groups (P = 0.78) or the genders (P = 0.24) as determined by
oth univariate and multivariate analyses (Table 3).a Tumor sizes available in 55 patients.
b Two  or more supratentorial sites.
c Follow-up of 87 patients (89.7%).
Tumor size and location
The  sizes of the tumors at the ﬁrst diagnosis were available
for 55 patients (Table 1). Most of them (70.9%) were supratento-
rial tumors >5 cm that had invaded or compressed the ventricular
system (60%) or had crossed over the middle line or invaded
infratentorial structures (10.9%). The other 21.8% of the supra-
tentorial tumors for which tumor locations had been recorded in
the medical records were more circumscribed, measuring >5 cm
(12.7%) or ≤5 cm (9.1%). The frontal lobe alone or in association
with the involvement of other supratentorial structures was  the
most affected (49 out of 94 cases (52.1%)). In 4 patients, the tumor
was located in infratentorial structures, with the cerebellum, pos-
terior fossa, and pons/medulla serving as the primary sites. Patient
survival was  not dependent upon tumor size (P = 0.22; Table 3) or
the primary sites of the tumor according to both univariate and
multivariate analyses (P = 0.08; Table 3).
Treatment and follow-up
The  study patients were diagnosed with GBM and treated before
the advent of temozolomide. Gross total resection (deﬁned as the
absence of residual tumor on postoperative CT and/or MR imag-
ing) was achieved in 31 cases (31.9%), and incomplete tumor
resection was  achieved in 66 (68.1%); however, there was no cor-
relation between the type of surgery and overall survival (P = 0.65).
Seventy-six of the 97 patients (78.3%) received adjuvant radio-
therapy (daily fractions of 1.5–2 Gy given 5 days per week for 6
weeks, for a total mean of 60.09 ± 0.54 Gy), and 57 of the 97 patients
(58.8%) underwent 6 cycles of adjuvant carmustine chemother-
apy. There was no difference in survival between patients treated
with surgery, surgery plus radiotherapy, or surgery plus radio-
therapy and chemotherapy according to both univariate (P = 0.15)
and multivariate analyses (P = 0.16, Table 3). At the last follow-
up, 87 patients were dead of disease (89.7%) and 10 were lost to
270 F.P. Saggioro et al. / Pathology – Research and Practice 210 (2014) 267–273
Table 2
FasL,  Fas, cleaved caspase-8, and cleaved caspase-3 immunoexpression in glioblas-
tomas and normal brain tissues according to the Mann–Whitney test.
Protein Glioblastoma Normal brain tissue P
N (%) N (%)
FasL
Positive 46 (50.5) 0 (0) <0.0001
Negative 45 (49.5) 25 (100)
Fas
Positive 62 (68.9) 4 (16) <0.0001
Negative 28 (31.1) 11 (84)
Cleaved caspase-8
Positive  43 (45.7) 8 (32) 0.0134
Negative 51 (54.3) 17 (68)
Cleaved caspase-3
Positive  32 (35.2) 1 (4)
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Table 3
Multivariate analysis of the Cox proportional-hazards regression model for survival
in patients with GBM.
Variable HR 95% CI P
Age 1.18 0.38–3.67 0.78
Gender 2.07 0.61–7.01 0.24
Tumor size 4.37 0.42–45.89 0.22
Primary site 4.83 0.83–28.14 0.08
Treatment
Surgery 1
Surg.  + Radiotherapy 1 0.16
Surg. + Rad. + Chemo 1.76 0.80–3.89
FasL
High  expression 1 0.85
Low expression 1.13 0.33–3.93
Fas
High  expression 1 0.11
Low expression 0.37 0.11–1.27
Cleaved caspase-8
High  expression 1 0.03
Low expression 11.5 1.25–106.95
Cleaved caspase-3
High  expression 1 0.08Negative 59 (64.8) 24 (96) 0.0011
ollow-up (10.3%). Excluding the patients who died during the
mmediate postoperative period (8 postoperative weeks) and the
 infratentorial cases, the mean follow-up period was 57.7 ± 53.6
eeks for 76 patients. All of these patients showed residual or
ecurrent disease during the follow-up period and died from causes
elated to their neoplasm. The overall 5-year cancer-speciﬁc sur-
ival rate was 1.3% (Table 1). Only 1 patient was alive after 5 years
f follow-up, and that patient died from disease 5.6 years after
iagnosis.
mmunohistochemistry
FasL, Fas, and cleaved caspase 8 were positively expressed
≥10% of tumor cells) in the cytoplasm of glioblastoma cells of 46
50.5%), 62 (68.9%), and 43 patients (45.7%), respectively. Cleaved
aspase-3 was positively expressed in the glioblastoma tissues of
2 patients (35.2%) in the following patterns: cytoplasmic posi-
ivity was observed in 16 tumors, nuclear positivity in 10, and
oth cytoplasmic and nuclear positivity in 6 (Table 2 and Fig. 1).
n normal brain tissues (control group), the expression of FasL,
as, and cleaved caspase-8 and cleaved caspase-3 occurred in the
ytoplasm of the glial cells of 0 (0%), 4 (16%), 8 (32%), and 1 (4%)
ontrol specimens, respectively (Table 2). The expressions of FasL
P < 0.0001), Fas (P < 0.0001), cleaved caspase-8 (P = 0.0134), and
leaved caspase-3 (P = 0.0011) were signiﬁcantly higher in glioblas-
oma than in normal glial tissues. Interestingly, only GBMs with
igh or low expression of cleaved caspase-8 were associated with
igniﬁcant differences in the overall survival (P = 0.0325), suggest-
ng that low immunoexpression (scores 0, 1, or 2) of cleaved
aspase-8 in glioblastomas was indicative of a more locally aggres-
ive tumor and was a prognostic indicator of reduced survival
median survival, 8.5 months; log-rank = 4.57, P = 0.0325, and haz-
rd ratio [95% conﬁdence interval] = 1.64 [1.04–2.74]) (Table 3 and
ig. 2). In addition, cleaved caspase-8 was determined to be an
ndependent prognostic factor according to a multivariate analysis
P = 0.03, Table 3).
In the glioblastomas, there were reasonable to good positive
orrelations between the expressions of FasL vs. Fas (r = 0.47,
 < 0.0001) and between Fas vs. cleaved caspase-8 (r = 0.41,
 < 0.0001) and poor positive correlations between Fas vs. cleaved
aspase-3 (r = 0.26, P = 0.014), FasL vs. cleaved caspase-8 (r = 0.22,
 = 0.0388), and cleaved caspase-8 and -3 (r = 0.31, P = 0.0026). No
orrelations were found among FasL, Fas, and cleaved caspase-8
nd cleaved caspase-3 in normal nervous tissue.
Both IDH1 and MGMT were negatively expressed in all 97 GBMs
espite the positive controls used for immunohistochemistry.Low expression 2.50 0.90–6.93
Discussion
Deregulation of the normal mechanism for programmed cell
death plays an important role in the pathogenesis and progres-
sion of gliomas [14,16,20,33]. Although evidence has accumulated
that gene mutations [22], microRNAs [11,36,47], growth factors
[17,18,37], RNA-binding proteins [45], DNA-binding transcription
factors [23], Ca2+ binding proteins [31], signal transduction proteins
[5,31], and DNA methylation [15] have critical roles in regulating
cell apoptosis, the signiﬁcance of the extrinsic apoptotic signaling
pathway for glioblastomas remains unclear [19,26]. In this study,
we used TMA  technology and immunohistochemistry to assess the
expression of proteins involved in the extrinsic pathway. We  looked
at FasL, Fas, cleaved caspase-8, and cleaved caspase-3 in treatment-
naïve human glioblastomas and normal glial cells from control
brains and examined these immunohistochemistry ﬁndings in the
context of the clinicopathological data of the study patients.
Death  receptors of the tumor necrosis factor (TNF) family,
including TNFR1, Fas (CD95/Apo-1), DR4/DR5, Apo-3 (DR3), and
their respective cognate ligands TNF-, FasL (CD95L/Apo-1L), TNF-
related apoptosis-inducing ligand (TRAIL/Apo-2L), and Apo-3L can
induce the extrinsic apoptotic pathway in the cytoplasm of tumor
and normal glial cells [1]. Molecular assays of the Fas signaling
pathway using yeast and eukaryotic cells have shown that after
the binding of FasL to the Fas receptor, Fas binds directly to the
adapter protein FADD (Mort1) and leads to apoptotic signal trans-
duction. In turn, FADD interacts with caspase-8 through its death
effector domain (DED), leading to DISC assembly and caspase-8
oligomerization, which drives its own activation in the cytoplasm
through self-cleavage. Subsequently, cleaved caspase-8 molecules
in the DISC activate downstream effector caspases, leading to the
cleavage of caspase-3 and apoptosis [4,7,21,27].
We demonstrated that malignant glial cells of glioblastomas
express Fas and FasL, an inducer of immunocyte cell death via the
Fas-mediated pathway of apoptosis. Because activated leukocytes
express abundant cell-surface Fas, the expression of FasL poten-
tially enables glioblastomas to counterattack and kill Fas-sensitive,
antitumor immune effector cells [19]. We  observed the augmented
expression of FasL in 50.5% of glioblastomas, in contrast to the
absence of its expression in normal glial tissue.
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Fig. 1. Immunoexpression of FasL, Fas, cleaved caspase-8 and cleaved caspase-3 in glioblastomas. (A–C) Cytoplasmic expression of FasL is observed in tumor cells; (A) shows
a  tumor with high FasL expression (score of 3); (B) (score of 1) and (C) (score of 1) show tumors with low FasL expression. (D–F) Cytoplasmic expression of Fas is observed
in tumor cells; (D) shows a tumor with high Fas expression (score 3); and E (score 1) and F (score 0) show tumors with low-to-negative Fas expression. (G–I) Cytoplasmic
expression of cleaved caspase-8 is observed in tumor cells; (G) shows a tumor with high cleaved caspase-8 expression (score 4); and H (score 1) and I (score 0) show tumors
w  of cle
h nd L (s
m
s
a
a
t
c
8ith  low and negative cleaved caspase-8 expression, respectively. (J–L) Expression
igh expression (score 4) of cleaved caspase-3 in tumor cells, whereas K (score 2) a
agniﬁcations: ×200).
In addition, we observed a signiﬁcant difference in Fas expres-
ion between glioblastomas (68.9%) and normal glial tissue (16%)
nd reasonable to good positive correlations between both FasL
nd Fas and Fas and cleaved caspase-8 in glioblastomas. Taken
ogether, our ﬁndings suggest that neoplastically transformed glial
ells increase the expression of FasL, Fas, and cleaved caspase-
, indicating the initiation of the extrinsic apoptotic pathway.aved caspase-3 in cytoplasm and/or in nuclei is observed in tumor cells. (J) shows
core 0) show tumor cells with low and negative expressions, respectively (original
Molecular  studies have demonstrated the high expression of Fas
and FasL in malignant glioma cells, and these ﬁndings support the
conclusion that the FasL-Fas-dependent apoptotic mechanism is
intact and functional [14,33].
When the expression of cleaved caspase-8 and cleaved caspase-
3 proteins was analyzed, we  found a signiﬁcant expression of
cleaved caspase-8 in 45.7% of the glioblastomas and 32% of the
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Fig. 2. Survival curves according to low (scores 0–2) and high (scores 3 and 4)
immunoexpression of cleaved caspase-8 in glioblastomas. Patients with tumors that
expressed low levels of the protein showed lower median survival (8.5 months)
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tompared  to patients with tumors that expressed high levels of the protein (median
urvival = 11.7 months) (Log-rank = 4.57, P = 0.0325, and hazard ratio [95% conﬁ-
ence  interval] = 1.64 [1.04–2.74]).
ormal glial tissues. Cleaved caspase-3 was expressed in 35.2% of
he glioblastomas and in only 4% of the normal glial tissues. In addi-
ion, we found that the low level of expression of cleaved caspase-8
n glioblastomas was associated with a median survival of 8.5
onths, which represents a signiﬁcant decrease in overall survival
ompared to patients with glioblastomas expressing high levels of
leaved caspase-8 (median survival of 11.7 months). This effect on
urvival was independent of treatment, gender, age, tumor size,
nd tumor location. Using a quantitative immunoblotting method,
shley et al. [2] also found that the caspase-8 protein levels in ex
ivo malignant gliomas varied substantially. Taken together, our
ndings suggest that high- or low-levels of expression of cleaved
aspase-8 and cleaved caspase-3 are independent of clinicopatho-
ogical features and are likely implicated in tumor progression.
We  observed poor correlations between Fas and cleaved
aspase-3, between FasL and cleaved caspase-8, and between
leaved caspase-8 and cleaved caspase-3 in the tumors. These
esults suggest that Fas-induced apoptosis is activated by the
xtrinsic pathway but is inhibited downstream. In fact, the Fas-
ediated apoptotic pathway can be inhibited in glioblastomas at
everal stages by RIP (receptor-interacting protein) [3], by c-FLIP
cellular Fas-associated death domain-like interleukin-1beta-
onverting enzyme-inhibitory protein) [13], by PEA-15/PED (phos-
hoprotein enriched astrocytes-15 kDa/phosphoprotein enriched
n diabetes) [14,37], by Bcl-2 [10,12,42] or by the cytokine response
odiﬁer A (CrmA) [28]. In addition, the activation of caspase-3 by
aspase-9 can be blocked by the high expression of inhibitor of
poptosis proteins (IAPs) in glioblastomas [28,35,44].
According to the literature, after FasL is bound to the Fas recep-
or, apoptotic signal transduction via the extrinsic pathway results
n the interaction of FADD with caspase-8 through their DED; how-
ver, in our study, we found poor correlations of cleaved caspase-8
xpression with FasL, Fas, and cleaved caspase-3 levels. This ﬁnd-
ng might be explained by the high expression in glioblastomas of
-FLIP and PED/PEA-15, which are protein inhibitors of caspase-8
ctivation and contain DED domains and can modify DISCs in the
on-raft fractions of the plasma membrane [3,13,43]. In fact, Bellail
t al. [3] showed that RIP, c-FLIP, and PED/PEA-15 can modify the
R5-mediated DISC in TRAIL-sensitive and resistant glioblastoma
ells, leading to the inhibition of caspase-8 cleavage and NF-B
ctivation.
Our results suggest that these proteins mediate the early
tages of the extrinsic apoptotic pathway in glioblastomas. FasL
inds to Fas and subsequently binds to FADD, transmitting the
ignal to activate the extrinsic pathway. At this stage, in glioblas-
omas, cleaved caspase-8 may  be inhibited, and consequently and Practice 210 (2014) 267–273
apoptosis of these cells may  also be inhibited. One could argue
that the signal strengths detected by immunohistochemistry in our
study, mainly for cleaved caspases-8 and cleaved caspase-3, did
not correlate with the apoptotic morphology in the GBMs. Two
fundamental explanations for these results could be postulated.
First, perinecrotic palisading cells, where apoptotic ﬁgures are more
often observed, were not included in the analyzed samples. Sec-
ond, there is evidence that the molecular modiﬁcation of the death
receptor-mediated DISC by RIP, c-FLIP and PED/PEA-15 may  control
caspase-8 cleavage and the initiation of apoptosis in glioblastoma
cells [3].
In  contrast to other studies [6,30], we  did not observe any sig-
niﬁcant differences in the survival of our patient cohort’s patient
survival between older and younger groups (<50 years vs. ≥50) or
between the three different treatment regimens, even when the
data were adjusted for the other variables studied. These diver-
gent results may  be due to the differences in the age ranges of the
cohorts. For example, Ohgaki et al. [30] studied 715 GBM patients
in the following age ranges: 6.9% were <39 years, 12.5% between 40
and 49 years, 21.1% between 50 and 59, 29.9% between 60 and 69,
22.1% between 70 and 79, and 7.6% >80 years. In addition, we  ana-
lyzed a smaller sample of patients (n = 97) compared to the Ohgaki
et al.’s cohort (n = 715). It is important to highlight that the age dis-
tribution of the population-based study of Ohgaki et al. [30] showed
greater frequency of younger and older patients (40.5% <50 years
and 29.7% ≥70) compared to our series (35.1% <50 years and 14.4%
≥70). This difference in the survival outcomes and responses to
treatment could be attributed to the different age distributions pre-
sented in both studies. Similarly, Burger and Green [6] studied 71
patients with GBM, 35 (49%) of whom were younger than 45 years
and 36 were older than 65 years (51%); however, in our series, 35.1%
of the patients were ≤49 years, and 41.2% were ≥60 years.
Unfortunately, we  did not obtain any conclusive labeling for
MGMT (instead, the controls were positive), though we used a
robust antibody (SPM287). In fact, the small tissue cores (1.0 mm)
and the well-known MGMT  immunolabeling heterogeneity may
have been limiting factors in our analysis, underscoring some of
the difﬁculties in using immunohistochemistry to assess MGMT
expression in formalin-ﬁxed parafﬁn-embedded GBM tissues,
as previously reported in other studies [34,46]. Similarly, the
immunohistochemistry for IDH1 was  negative in all GBM tissue
cores (with positive controls). However, it is important to note
that the majority (if not all) of our GBM cases were primary GBMs
that did not contain the IDH1 mutation. Although we used a gen-
eral IDH1-antibody instead of the well-established antibody for
the dominant mutant variant of the enzyme (IDH1-R132H), we
do not believe that it impacted our results because no IDH1-
immunopositive cells could be found in the TMAs. Furthermore,
the staining of such small areas with the mutation-speciﬁc antibody
may be problematic.
In  conclusion, 50.5% of the glioblastomas expressed variable lev-
els of FasL, 68.9% expressed Fas, 45.7% expressed cleaved caspase-8,
and 35.2% expressed cleaved caspase-3. Moreover, glioblastoma
tumors should contain a functional mechanism for the extrinsic
apoptotic pathway. Our ﬁndings suggest that Fas–Fas-ligand down-
stream signal transduction could be inhibited, especially at the
stage of caspase-8 activation, thereby establishing a major mech-
anism for the evasion of apoptosis by these tumors. Furthermore,
our ﬁndings highlight the study of Ho et al. [16], who  showed that
FasL and Fas delivery by a glioma-speciﬁc and cell cycle-dependent
HSV-1 amplicon virus enhances apoptosis in high-grade gliomas,
and may  be useful as an adjuvant therapy to complement the
current therapeutic regimens for human gliomas. In addition, the
low immunoexpression of cleaved caspase-8 (0 to <50% of faintly
positive tumor cells) in glioblastomas was an independent prog-
nosticator of slightly decreased disease-speciﬁc survival, compared
search
w
F
w
s
C
A
p
d
s
F
P
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[46] M.  Weller, R. Stupp, G. Reifenberger, et al., MGMT  promoter methylation inF.P. Saggioro et al. / Pathology – Re
ith tumors that expressed higher levels of cleaved caspase-8.
urther studies examining molecular targets in the extrinsic path-
ay of apoptosis are needed and may  reveal promising treatment
trategies for glioblastomas.
onﬂict  of interest
The  authors declare that there are no conﬂicts of interest.
cknowledgments
We  would like to thank Joaquim Soares de Almeida, who pre-
ared the tissue microarrays, and Maria José Carregosa Pinheiro
os Santos for their excellent technical assistance. This work was
upported by Fundac¸ ão de Amparo a Pesquisa do Estado de São Paulo-
APESP (04/09932-4). Writing assistance was provided by BioMed
roofreading, Cleveland, USA.
eferences
[1] A. Ashkenazi, V.M. Dixit, Death receptors: signaling and modulation, Science
281 (1998) 1305–1308.
[2] D.M. Ashley, C.D. Riffkin, A.M. Muscat, et al., Caspase 8 is absent or low in many
ex vivo gliomas, Cancer 104 (2005) 1487–1496.
[3]  A.C. Bellail, M.C.L. Tse, J.H. Song, et al., DR5-mediated DISC controls caspase-8
cleavage and initiation of apoptosis in human glioblastomas, J. Cell. Mol. Med.
14 (2010) 1303–1317.
[4] M.P. Boldin, T.M. Goncharov, Y.V. Goltsev, et al., Involvement of MACH, a novel
MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced
cell death, Cell 85 (1996) 803–815.
[5] E.C. Brantley, E.N. Benveniste, Signal transducer and activator of transcription-
3: a molecular hub for signaling pathways in gliomas, Mol. Cancer Res. 6 (2008)
675–684.
[6]  P.C. Burger, S.B. Green, Patient age, histologic features, and length of survival
in patients with glioblastoma multiforme, Cancer 59 (1987) 1617–1625.
[7] A.M. Chinnaiyan, K. O’Rourke, M.  Tewari, et al., FADD, a novel death domain-
containing protein interacts with the death domain of Fas and initiates
apoptosis, Cell 81 (1995) 505–512.
[8] L.M. Deangelis, Brain tumors, N. Engl. J. Med. 344 (2001) 114–123.
[9] R. Dubrow, A.S. Darefsky, D.I. Jacobs, et al., Time trends in glioblastoma multi-
forme survival: the role of temozolomide, Neuro Oncol. (2013) [Epub ahead of
print, Sep 17].
10] S. Fulda, E. Meyer, K.M. Debatin, Inhibition of TRAIL-induced apoptosis by Bcl-2
overexpression, Oncogene 21 (2002) 2283–2294.
11]  G. Gabriely, M.  Yi, R.S. Narayan, et al., Human glioma growth is controlled by
microRNA-10b, Cancer Res. 71 (2011) 3563–3572.
12]  J. George, N.L. Banik, S.K. Ray, Combination of taxol and Bcl-2 siRNA induces
apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and
tumour growth, J. Cell. Mol. Med. 13 (2009) 4205–4218.
13] K. Grund, R. Ahmadi, F. Jung, et al., Troglitazone-mediated sensitization to
TRAIL-induced apoptosis is regulated by proteasome-dependent degradation
of FLIP and ERK1/2-dependent phosphorylation of BAD, Cancer Biol. Ther. 7
(2008) 1982–1990.
14] C. Hao, F. Beguinot, G. Condorelli, et al., Induction and intracellular regulation of
tumor necrosis-related apoptosis-inducing ligand (TRAIL) mediated apoptosis
in human malignant glioma cells, Cancer Res. 61 (2001) 1162–1170.
15] E. Hervouet, E. Debien, L. Campion, et al., Folate supplementation limits
the aggressiveness of glioma via the remethylation of DNA repeats element
and genes governing apoptosis and proliferation, Clin. Cancer Res. 15 (2009)
3519–3529.
16]  I.A. Ho, W.H. Ng, P.Y. Lam, FasL and FADD delivery by a glioma-speciﬁc and cell
cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human
brain tumors, Mol. Cancer 9 (2010) 270.
17]  E.C. Holland, W.P. Hively, R.A. De Pinho, et al., A constitutively active epidermal
growth factor receptor cooperates with disruption of G1 cell-cycle arrest path-
ways to induce glioma-like lesions in mice, Genes Dev. 12 (1998) 3675–3685.
18] S.S. Hsu, C.H. Chen, G.S. Liu, et al., Tumorigenesis and prognostic role of
hepatoma-derived growth factor in human gliomas, J. Neurooncol. 107 (2012)
101–109.
[ and Practice 210 (2014) 267–273 273
19] T. Jansen, B. Tyler, J.L. Mankowski, et al., FasL gene knock-down therapy
enhances the antiglioma immune response, Neuro Oncol. 12 (2010) 482–489.
20]  Z.F. Jia, Q. Huang, C.S. Kang, et al., Overexpression of septin 7 suppresses glioma
cell growth, J. Neurooncol. 98 (2010) 329–340.
21]  F.C. Kischkel, S. Hellbardt, I. Behrmann, et al., Cytotoxicity-dependent APO-
1 (Fas/CD95)-associated proteins form a death-inducing signaling complex
(DISC) with the receptor, EMBO J. 14 (1995) 5579–5588.
22] P. Kleihues, P.C. Burger, K.D. Aldape, et al., Glioblastoma, in: D.N. Louis, H.
Ohgaki, O.D. Wiestler, W.K. Cavenee (Eds.), WHO  Classiﬁcation of Tumors of
the Central Nervous System, fourth ed., IARC, Lyon, 2007, pp. 33–49.
23] D. Liao, Emerging roles of the EBF family of transcription factors in tumor
suppression, Mol. Cancer Res. 7 (2009) 1893–1901.
24]  H. Mao, D.G. Lebrun, J. Yang, et al., Deregulated signaling pathways in glioblas-
toma multiforme: molecular mechanisms and therapeutic targets, Cancer
Invest. 30 (2012) 48–56.
25] G.P. Margison, P. Kleihues, Chemical carcinogenesis in the nervous system. Pref-
erential accumulation of O6-methylguanine in rat brain deoxyribonucleic acid
during repetitive administration of N-methyl-N-nitrosourea, Biochem. J. 148
(1975) 521–525.
26] F. Mollinedo, C. Gajate, Fas/CD95 death receptor and lipid rafts: new targets for
apoptosis-directed cancer therapy, Drug Resist. Updat. 9 (2006) 51–73.
27] M.  Muzio, B.R. Stockwell, H.R. Stennicke, et al., An induced proximity model for
caspase-8 activation, J. Biol. Chem. 273 (1998) 2926–2930.
28] M.  Nagane, G. Pan, J.J. Weddle, et al., Increased death receptor 5 expression
by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity
with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in
vivo, Cancer Res. 60 (2000) 847–853.
29] S. Nagata, P. Golstein, The Fas death factor, Science 267 (1995) 1449–1456.
30] H. Ohgaki, P. Dessen, B. Jourde, et al., Genetic pathways to glioblastoma: a
population-based study, Cancer Res. 64 (2004) 6892–6899.
31] P. Pu, Z. Zhang, C. Kang, et al., Downregulation of Wnt2 and beta-catenin by
siRNA suppresses malignant glioma cell growth, Cancer Gene Ther. 16 (2009)
351–361.
32]  J.C. Reed, Mechanisms of apoptosis, Am.  J. Pathol. 157 (2000) 1415–1430.
33] C.D. Riffkin, A.Z. Gray, C.J. Hawkins, et al., Ex vivo pediatric brain tumors express
Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction, Neuro
Oncol. 3 (2001) 229–240.
34] F.J. Rodriguez, S.N. Thibodeau, R.B. Jenkins, et al., MGMT  immunohistochemical
expression  and promoter methylation in human glioblastoma, Appl. Immuno-
histochem. Mol. Morphol. 16 (2008) 59–65.
35]  M.D. Siegelin, T. Gaiser, Y. Siegelin, The XIAP inhibitor embelin enhances TRAIL-
mediated apoptosis in malignant glioma cells by down-regulation of the short
isoform of FLIP, Neurochem. Int. 55 (2009) 423–430.
36]  J. Silber, C.D. James, J.G. Hodgson, MicroRNAs in gliomas: small regulators of a
big problem, Neuromol. Med. 11 (2009) 208–222.
37]  A. Soeda, A. Inagaki, N. Oka, et al., Epidermal growth factor plays a crucial role
in mitogenic regulation of human brain tumor stem cells, J. Biol. Chem. 283
(2008) 10958–10966.
38] J.H. Song, A. Bellail, M.C. Tse, et al., Human astrocytes are resistant to Fas ligand
and tumor necrosis factor-related apoptosis-inducing ligand-induced apopto-
sis, J. Neurosci. 26 (2006) 3299–3308.
39] R. Stupp, W.P. Mason, M.J. van den Bent, et al., Radiotherapy plus concomi-
tant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med. 352 (2005)
987–996.
40] A. Thorburn, Death receptor-induced cell killing, Cell Signal. 16 (2004) 139–144.
41]  P.B. Thornhill, J.B. Cohn, G. Drury, et al., A proteomic screen reveals novel Fas
ligand interacting proteins within nervous system Schwann cells, FEBS Lett.
581 (2007) 4455–4462.
42] L.F. Tirapelli, P.H. Bolini, D.P. Tirapelli, et al., Caspase-3 and Bcl-2 expression in
glioblastoma: an immunohistochemical study, Arq. Neuropsiquiatr. 68 (2010)
603–607.
43]  M.G. Valmiki, J.W. Ramos, Death effector domain-containing proteins, Cell. Mol.
Life Sci. 66 (2009) 814–830.
44] S.H. Vellanki, A. Grabrucker, S. Liebau, et al., Small-molecule XIAP inhibitors
enhance gamma-irradiation-induced apoptosis in glioblastoma, Neoplasia 11
(2009) 743–752.
45] D.T. Vo, K. Abdelmohsen, J.L. Martindale, et al., The oncogenic RNA-binding
protein Musashi1 is regulated by HuR via mRNA translation and stability in
glioblastoma cells, Mol. Cancer Res. 10 (2012) 143–155.malignant gliomas: ready for personalized medicine, Nat. Rev. Neurol. 6 (2010)
39–51.
47]  X. Zhou, J. Zhang, Q. Jia, et al., Reduction of miR-21 induces glioma cell apoptosis
via activating caspase 9 and 3, Oncol. Rep. 24 (2010) 195–201.
